AC Immune SA announced that Interim CEO Martin Zügel will present at the Jefferies Global Healthcare Conference 2026 in London, discussing their lead Parkinson's disease drug candidate ACI-7104 and other pipeline updates. ACI-7104 is in Phase 2 trials targeting early-stage Parkinson's by addressing misfolded alpha-synuclein proteins, aiming to slow disease progression. The company also highlighted other programs including ACI-19764 and a small-molecule Morphomer. This presentation underscores AC Immune's ongoing efforts to develop disease-modifying therapies for neurodegenerative diseases with significant unmet needs.
AC Immune's presentation at Jefferies Global Healthcare Conference 2026 is context for readers following health stocks. For readers following health stocks, here is Pluang's market snapshot as of Nov 11, 2026 19:11 WIB: Of 150 priced US health-sector stocks, 67 rose and 75 fell. Notable movers include DNA at USD 12.49 (+4.00%), RXRX at USD 3.70 (+3.93%), and REGN at USD 883.02 (-3.61%).
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
